[HTML][HTML] The clinical progress of mRNA vaccines and immunotherapies

AJ Barbier, AY Jiang, P Zhang, R Wooster… - Nature …, 2022 - nature.com
The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …

[HTML][HTML] Advances in COVID-19 mRNA vaccine development

E Fang, X Liu, M Li, Z Zhang, L Song, B Zhu… - Signal transduction and …, 2022 - nature.com
To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …

[HTML][HTML] Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis

C Stein, H Nassereldine, RJD Sorensen, JO Amlag… - The Lancet, 2023 - thelancet.com
Background Understanding the level and characteristics of protection from past SARS-CoV-
2 infection against subsequent re-infection, symptomatic COVID-19 disease, and severe …

[HTML][HTML] Covid-19 vaccines—immunity, variants, boosters

DH Barouch - New England Journal of Medicine, 2022 - Mass Medical Soc
Covid-19 Vaccines — Immunity, Variants, Boosters | New England Journal of Medicine Skip to
main content The New England Journal of Medicine homepage Advanced Search SEARCH …

[HTML][HTML] The biological and clinical significance of emerging SARS-CoV-2 variants

K Tao, PL Tzou, J Nouhin, RK Gupta… - Nature Reviews …, 2021 - nature.com
The past several months have witnessed the emergence of SARS-CoV-2 variants with novel
spike protein mutations that are influencing the epidemiological and clinical aspects of the …

COVID-19 vaccination: The road ahead

DM Altmann, RJ Boyton - Science, 2022 - science.org
A diverse array of successful, first-generation SARS-CoV-2 vaccines have played a huge
role in efforts to bring the COVID-19 pandemic under control, even though inequitable …

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

PB Gilbert, DC Montefiori, AB McDermott, Y Fong… - Science, 2022 - science.org
In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …

[HTML][HTML] Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

S Feng, DJ Phillips, T White, H Sayal, PK Aley, S Bibi… - Nature medicine, 2021 - nature.com
The global supply of COVID-19 vaccines remains limited. An understanding of the immune
response that is predictive of protection could facilitate rapid licensure of new vaccines. Data …

[HTML][HTML] Immunological mechanisms of vaccine-induced protection against COVID-19 in humans

M Sadarangani, A Marchant… - Nature Reviews …, 2021 - nature.com
Most COVID-19 vaccines are designed to elicit immune responses, ideally neutralizing
antibodies (NAbs), against the SARS-CoV-2 spike protein. Several vaccines, including …

[HTML][HTML] SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity

C Motozono, M Toyoda, J Zahradnik, A Saito… - Cell host & …, 2021 - cell.com
Many SARS-CoV-2 variants with naturally acquired mutations have emerged. These
mutations can affect viral properties such as infectivity and immune resistance. Although the …